Sino Biopharmaceutical (FRA:SMZ1) Margin of Safety % (DCF Dividends Based) : 18.51% (As of May. 01, 2024)

View and export this data going back to . Start your Free Trial

What is Sino Biopharmaceutical Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

As of today (2024-05-01), Sino Biopharmaceutical's Predictability Rank is 3-Stars. Sino Biopharmaceutical's intrinsic value calculated from the Discounted Dividend model is €0.38 and current share price is €0.3178. Consequently,

Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based) using Discounted Dividend model is 18.51%.

Competitive Comparison of Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based) falls into.

Sino Biopharmaceutical Margin of Safety % (DCF Dividends Based) Calculation

Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based) for today is calculated as

Margin of Safety % (DCF Dividends Based)	=	(Intrinsic Value: DCF (Dividends Based)	-	Current Price)	/	Intrinsic Value: DCF (Dividends Based)
	=	(0.39	-	0.3178)	/	0.39
	=	18.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Dividend model with default parameters.

Sino Biopharmaceutical Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (FRA:SMZ1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (FRA:SMZ1) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (FRA:SMZ1) Headlines

No Headlines